Docoh
Loading...

CLNH Clinigence

Filed: 19 May 20, 2:20pm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) May 19, 2020

Clinigence Holdings, Inc.

(Exact name of registrant as specified in its charter)

Delaware000-5386211-3363609

(State or other jurisdiction

of incorporation)

(Commission File Number)

(IRS EmployerIdentification No.)

 

55 Ivan Allen Jr. Blvd. NW, #875

Atlanta, Georgia

30308
(Address of principal executive offices)(Zip Code)

 

Registrant’s telephone number, including area code: (678) 607-6393

(Former name or former address, if changed since last report) 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

Title of each class 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, $0.001 par value CLNH OTCMKTS
     

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended tranistion period for complying with any new or revised financial accounting standards provided pursuant to Section 12(a) of the Exchange Act. ☐ 

 1 

 

 

Item 5.02Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

 

Resignation of Member of the Board of Directors

 

On May 16, 2020, the Board of Directors (the “Board”) of Clinigence Holdings, Inc. (the “Company”) accepted the resignation of Dr. Lawrence Schimmel from the Board and related responsibilities on the Governance and Nominating Committee. Dr. Schimmel’s resignation is not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices. Dr. Schimmel will remain as an officer of the Company in his position as Chief Medical Officer. Effective upon Dr. Schimmel’s resignation as a director, the Company’s Board will be reduced from nine to eight directors.

Item 9.01Financial Statements and Exhibits.

 

(d) Exhibits.

The exhibits listed in the following Exhibit Index are filed as part of this Current Report on Form 8-K.

 

Exhibit No.Description
99.1Letter of Resignation from Lawrence Schimmel, dated May 16, 2020

 

 2 

 

 

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

  Clinigence Holdings, inc.
   
Date: May 19, 2020 By:/s/ Elisa Luqman
  Elisa Luqman
  Chief Financial Officer

 3